Biotechnology

OSR released FY2025 Q3 earnings on November 12 (EST), actual revenue USD 627.75K, actual EPS USD -0.1223

OSR released FY2025 9 Months Earnings on November 12 (EST), with actual revenue of USD 2.525 M and EPS of USD -1.147

OSR released FY2025 Q2 earnings on August 14 (EST), actual revenue USD 1.136M, actual EPS USD 0.02

OSR released FY2025 Semi-Annual earnings on August 14 (EST), actual revenue USD 1.897 M, actual EPS USD -0.7298

OSR released FY2024 Q2 earnings on August 14 (EST), actual revenue USD 881.83 K, actual EPS USD -0.41

OSR released FY2024 Semi-Annual Earnings on August 14, 2025 (EST), with actual revenue of USD 1.792M and EPS of USD -1.0017

OSR Holdings Reports Q1 2025 Earnings: Net Sales Down 16%, Sees Increased R&D Expenses

OSR released FY2024 Q1 earnings on May 20 (EST), actual revenue USD 910.23K, actual EPS USD -0.5967

OSR released FY2025 Q1 earnings on May 20 (EST), actual revenue USD 761.27K, actual EPS USD -1.0446

OSR released FY2023 Q4 earnings on April 22, 2025 (EST), with actual revenue of USD -2.421 M and EPS of USD 0

OSR released FY2024 Q4 earnings on April 22, 2025 (EST), with actual revenue of USD -2.395 M and EPS of USD 0.474

OSR released FY2023 Annual Earnings on April 22 Post-Market (EST) with actual revenue USD 0 and actual EPS USD 0

OSR released FY2024 Annual Earnings on April 22 Post-Market (EST), actual revenue USD 0, actual EPS USD -0.54

OSR released FY2024 Q3 earnings on February 21, 2025 (EST) with actual revenue of USD 823 K and EPS of USD -1.56

OSR released FY2024 9 Months Earnings on February 21, 2025 (EST), actual revenue USD 2.647 M, actual EPS USD -2.8526

OSR released FY2023 Q3 earnings on February 21 (EST) with actual revenue of USD 858.45 K and EPS of USD -2.1288

AdvisorShares MSOS 2x Daily ETF

cbdMD

Tryhard

Roundhill Cannabis ETF

Neo-Concept

Amplify Seymour Cannabis ETF

AdvisorShares Pure US Cannabis ETF

Canopy Growth

RYTHM

Tilray Brands

ADMA生物制药

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel制药

OpGen

福泰制药

再生元制药

Argenx

阿里拉姆制药

百济神州

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap